Commercial-Scale Cell & Gene Therapy CDMOs

· updated as new inspection, certificate, and trial data enters the platform

Cell & Gene Therapy manufacturers on CDMO Signal: 52 listed. 12 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Bristol Myers Squibb (CGT Mfg) (in-house manufacturer, Signal Score 87), Novartis (in-house manufacturer, Signal Score 85.4) and City of Hope (T Cell Manufacturing) (academic or national centre, Signal Score 84). Outside that set, higher Signal Scores on this list include Pharmaron (Signal Score 86.9), FUJIFILM Diosynth Biotechnologies (Signal Score 86.7) and Charles River Laboratories (Signal Score 86.3). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology. This page is the commercial-scale filter: a high Signal Score or a broad ClinicalTrials.gov footprint. It is not a list of approved commercial products.

52
CDMOs tracked
52
Fully scored
28
With FDA records
140
FDA inspections
294
EMA/MHRA GMP certs
2
Warning letters

Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.

For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).

FDA inspection outcomes across these CDMOs: 64 NAI (no action), 73 VAI (voluntary action), 3 OAI (official action). Leading inspection & GMP sites: United States (100), UNITED KINGDOM (61), Denmark (52), Austria (39), Germany (33).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing all operator types.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
BMS
Bothell, WA · Warren, NJ
Fully evidenced
In-house manufacturer
87.0 97.2 8 insp · 2 GMP 2026-04-28 · NAI — 585 programs
2
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
86.9 100.0 5 insp · 1 GMP 2026-08-14 · NAI Available —
3
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
86.7 100.0 0 insp · 35 GMP None on file Expanding —
4
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
5
Basel, Switzerland
Fully evidenced
In-house manufacturer
85.4 97.4 17 insp · 51 GMP 2026-06-24 · NAI — 135 programs
6
KB
Durham, NC · Boulder, CO
Hiring · 97+ open roles
84.1 98.5 2 insp · 1 GMP 2026-04-01 · VAI Limited —
7
COH
Duarte, CA
Fully evidenced
Academic / national centre
84.0 97.3 3 insp · 0 GMP 2025-08-20 · VAI — 213 programs
8
AJ
San Diego, CA · Osaka, JP
83.5 100.0 0 insp · 1 GMP None on file — —
9
TK
Boston, MA · Zurich, CH
Fully evidenced
Also makes its own products
83.4 100.0 4 insp · 20 GMP 2026-04-10 · NAI — 100 programs
10
MN
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
83.1 99.2 3 insp · 4 GMP 2025-11-25 · NAI Limited —
11
RP
Keele, UK · Sodertalje, SE
82.9 100.0 0 insp · 3 GMP None on file — —
12
WB2
Shanghai, CN · Wuxi, CN
82.7 99.6 1 insp · 4 GMP 2026-07-03 · VAI — —
13
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
81.9 98.8 2 insp · 2 GMP 2025-04-28 · VAI — 22 programs
14
LB
Incheon, KR · Syracuse, NY
Hiring · 8 open roles
81.6 100.0 2 insp · 0 GMP 2026-09-18 · NAI — —
15
SC
Prague, Czech Republic
81.6 100.0 0 insp · 5 GMP None on file — —
16
EF
Planegg, DE · San Diego, CA
81.6 100.0 7 insp · 0 GMP 2026-05-15 · NAI — —
17
NW
Vilnius, LT; Waltham (MA), USA
Hiring · 16 open roles
80.8 100.0 0 insp · 8 GMP None on file Available —
18
CF
Les Ulis, FR
80.3 100.0 0 insp · 4 GMP None on file — —
19
SG
Bengaluru, India
Hiring · 4 open roles
80.3 100.0 3 insp · 0 GMP 2025-02-20 · NAI — —
20
BR
Glasgow, UK · Rockville, MD
Hiring · 16 open roles
Also makes its own products
80.3 97.2 6 insp · 10 GMP 2026-05-13 · VAI — —
21
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
22
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
79.5 100.0 — None on file Available —
23
BV
Turku, Finland
Hiring · 2 open roles
79.4 99.8 1 insp · 4 GMP 2024-12-19 · VAI — —
24
RC
Edinburgh, UK · Hopkinton, MA
Hiring · 8 open roles
79.3 96.8 1 insp · 1 GMP 2025-01-21 · VAI Available —
25
UM
Boston, MA
78.7 96.7 2 insp · 0 GMP 2025-12-18 · VAI — —
26
GZ
Indianapolis, IN · Lexington, MA
Hiring · 26 open roles
78.1 100.0 1 insp · 0 GMP 2025-08-27 · NAI Available —
27
AA
Rockville, MD · Alachua, FL · Munich, DE
78.1 100.0 0 insp · 1 GMP None on file — —
28
NG
Leiden, NL
78.1 100.0 0 insp · 1 GMP None on file — —
29
ET
Jumet, BE
78.1 100.0 0 insp · 4 GMP None on file — —
30
PG
Berlin, DE
78.1 100.0 0 insp · 4 GMP None on file — —
31
CE
Basel, Switzerland
Hiring · 4 open roles
78.1 100.0 0 insp · 1 GMP None on file — —
32
XP
Bristol, United Kingdom
78.1 100.0 0 insp · 1 GMP None on file — —
33
AD
London, United Kingdom
78.1 100.0 0 insp · 2 GMP None on file — —
34
GP
San Diego, CA
78.1 100.0 0 insp · 1 GMP None on file — —
35
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
77.6 93.2 19 insp · 10 GMP 2026-06-30 · NAI Available 2 programs
36
AG2
San Carlos, CA
77.6 98.8 1 insp · 0 GMP 2025-04-18 · VAI — —
37
CS
Los Angeles, CA
Hiring · 1 open role
Fully evidenced
Academic / national centre
77.3 92.9 2 insp · 0 GMP 2025-03-14 · NAI — 34 programs
38
VG
San Sebastián, Spain
Hiring · 3 open roles
76.8 100.0 0 insp · 4 GMP None on file Available —
39
SY
Stirling, United Kingdom
76.8 100.0 1 insp · 8 GMP 2025-01-31 · NAI — —
40
CY
Toulouse, FR
76.8 100.0 0 insp · 2 GMP None on file — —
41
CN
Luxembourg, LU
76.8 100.0 0 insp · 1 GMP None on file — —
42
HH
London, United Kingdom
76.8 100.0 0 insp · 4 GMP None on file — —
43
FH
Seattle, WA
Academic / national centre
76.3 — — None on file — 454 programs
44
OX
Oxford, United Kingdom
Hiring · 4 open roles
Fully evidenced
Also makes its own products
76.2 100.0 2 insp · 13 GMP 2024-06-17 · NAI Available 7 programs
45
Tampa, FL
Hiring · 311 open roles
76.1 77.3 24 insp · 39 GMP 2026-05-22 · VAI
Warning letter 2025-11-20
— —
46
BC
Bengaluru, India
Hiring · 48 open roles
75.7 93.1 7 insp · 2 GMP 2025-09-03 · VAI — —
47
BY
Berkeley, CA
In-house manufacturer
75.2 — — None on file — 126 programs
48
CI
Cincinnati, OH
Hiring · 2 open roles
Fully evidenced
Academic / national centre
75.1 99.6 2 insp · 0 GMP 2025-02-05 · NAI — 1 program
49
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
73.6 95.6 1 insp · 0 GMP 2025-01-21 · VAI Available 9 programs
50
MB
Bergisch Gladbach, Germany
Fully evidenced
73.0 100.0 0 insp · 2 GMP None on file — 8 programs
51
IU
Indianapolis, IN
Academic / national centre
66.3 — — None on file — 49 programs
52
IO
Philadelphia, PA
Hiring · 9 open roles
In-house manufacturer
65.9 — — None on file — 31 programs
How we score CDMOs →

What to evaluate in a Cell & Gene Therapy CDMO

Integrated vs point-solution CDMO
Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.
Regulatory record by process class
Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.
Chain-of-identity + cold chain
Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.
Commercial track record
For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.

Cell & Gene Therapy CDMOs — Frequently Asked Questions

Who are the top Cell & Gene Therapy CDMOs?
Among Cell & Gene Therapy manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are Bristol Myers Squibb (CGT Mfg), Novartis, City of Hope (T Cell Manufacturing). The table above is the full list. CDMOs cannot pay to change a score.
How many Cell & Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 28 Cell & Gene Therapy CDMOs with FDA inspection records and 294 EMA/MHRA GMP certificates across the group.
What should I look for in a cell and gene therapy CDMO?
Start with process class match — cell therapy vs vector vs both. For ex vivo programs benefit from integrated CDMOs. Verify inspection record on the specific process class, confirm capacity match to your patient volume, and prioritize CDMOs with commercial-scale posture for late-stage work.
How many cell and gene therapy CDMOs does CDMO Signal track?
The table on this page is the live list: the union of cell therapy, AAV, lentiviral, adenoviral, and gene-therapy-tagged manufacturers. This is the broadest advanced-therapy candidate list on the platform. CDMOs cannot pay to change a score.
Related modalities
Cell Therapy CDMOs AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Gene Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Viral Vector